Literature DB >> 21958000

Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease.

Hiroaki Hayashi, Chiaki Kuwabara, Kenichi Tarumi, Eiichi Makino, Wataru Fujimoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21958000     DOI： 10.1111/j.1346-8138.2011.01346.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

1.  Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.

Authors:  Vasiliki A Zampeli; Undine Lippert; Georgios Nikolakis; Evgenia Makrantonaki; Thrasivoulos G Tzellos; Ulf Krause; Christos C Zouboulis
Journal:  J Dermatol Case Rep       Date:  2015-09-30

2.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

3.  Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.

Authors:  Lucas Guillo; Ferdinando D'Amico; Mélanie Serrero; Karine Angioi; Damien Loeuille; Antonio Costanzo; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-08-10       Impact factor: 4.623

4.  Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis.

Authors:  K Arivarasan; Vaishali Bhardwaj; Sukrit Sud; Sanjeev Sachdeva; Amarender Singh Puri
Journal:  Intest Res       Date:  2016-10-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.